This approach could also predict the HER3-targeted therapeutic efficacy of tyrosine kinase inhibitors neratinib and anti-HER3 antibody patritumab in advanced solid tumors, including breast cancer (Sergina et al., 2007; LoRusso et al., 2013; Mukai et al., 2016; Hyman et al., 2018). Here, ERBB3 is linked to breast carcinoma.